RGS4 promotes the progression of gastric cancer through the focal adhesion kinase/phosphatidyl-inositol-3-kinase/protein kinase B pathway and epithelial-mesenchymal transition

Table 1 Association between regulator of G protein signaling 4 expression and clinicopathological characteristics of patients with gastric cancer

Characteristics	RGS4 expression		P value
	Low group (n = 45)	High group (n = 45)
Age, median (IQR)	64 (60, 68)	66 (61, 70)	0.199
Gender, n (%)			0.806
Female	12 (13.3)	10 (11.1)
Male	33 (36.7)	35 (38.9)
T stage, n (%)			0.011
T1	9 (10)	1 (1.1)
T2	9 (10)	4 (4.4)
T3	7 (7.8)	10 (11.1)
T4	20 (22.2)	30 (33.3)
N stage, n (%)			0.038
N0	21 (23.3)	11 (12.2)
N1	10 (11.1)	9 (10)
N2	6 (6.7)	5 (5.6)
N3	8 (8.9)	20 (22.2)
M stage, n (%)			1.000
M0	43 (47.8)	42 (46.7)
M1	2 (2.2)	3 (3.3)
Grade, n (%)			0.002
G1	16 (17.8)	6 (6.7)
G2	18 (20)	12 (13.3)
G3	11 (12.2)	27 (30)
TNM stage, n (%)			0.011
Stage I	15 (16.7)	3 (3.3)
Stage II	11 (12.2)	12 (13.3)
Stage III	17 (18.9)	27 (30)
Stage IV	2 (2.2)	3 (3.3)
OS (month)
Median (range)	28 (7-70)	19 (3-56)	0.004

RGS4: Regulator of G protein signaling 4; IQR: Interquartile range; TNM: Tumor-node-metastasis; OS: Overall survival.